丹参多酚酸盐治疗脑梗死的临床疗效和血液流变学的影响

目的评价丹参多酚酸盐治疗脑梗死的临床疗效及对血液流变学的影响,探讨其临床适用性。方法选择从2012年5月—2014年5月于该院就诊的130例脑梗死患者,简单随机分为试验组65例和对照组65例,对照组患者静点舒血宁注射液,试验组患者则采用丹参多酚酸盐静点。观察两组患者治疗后的临床疗效及对血液流变学的影响。结果试验组患者的治疗总有效率为93.85%,对照组患者的治疗总有效率为81.54%,两组患者的治疗总有效率比较,差异有统计学意义（χ^2=4.5614,P=0.0327 P〈0.05）,两组患者治疗前全血高切粘度、全血低切粘度、血浆比粘度、红细胞比容及纤维蛋白原指标均差异无统计学意义（P〉0.05）,治疗后明显改善,差异有统计学意义（P〈0.05）,且试验组患者上述指标的改善程度明显优于对照组患者,差异有统计学意义（P〈0.05）。结论丹参多酚酸盐治疗脑梗死有很好的临床疗效,且可以显著改善血流变情况,降低了脑梗死病情进展的风险,适合临床长期推广应用。

The Clinical Efficacy of Salvianolate in the Treatment of Cerebral Infarction and the Effect on the Hemorheology

Objective To evaluate the clinical efficacy of Salvianolate in the treatment of cerebral infarction and the effect on the hemorheology, and discuss its clinical applicability. Methods 130 cases with cerebral infarction admitted in our hospital from May2012 to May 2014 were simply and randomly divided into the experimental group and the control group with 65 cases in each. Patients in the control group were given intravenous drip of Shuxuening, and patients in the experimental group were given intravenous drip of Salvianolate. The clinical efficacy and the effect of the treatment on hemorheology were observed between the two groups. Results The total effective rate of the experimental group was 93.85%, and that of the control group was 81.54%, the difference was statistically significant（χ^2=4.5614, P=0.0327, P〈0.05）. Before treatment, the differences in whole blood high shear viscosity, whole blood low shear viscosity, plasma viscosity, erythrocrit, fibrinogen index between the two groups were not statistically significant（P〉0.05）, but significantly improved after treatment, the differences were statistically significant（P〈0.05）, and the degree of improvement in these indicators of the experimental group were significantly better than those of the control group, the differences were statistically significant（P〈0.05）. Conclusion Salvianolate has good clinical efficacy in the treatment of cerebral infarction, which can significantly improve the conditions of blood flow, and reduce the risk of cerebral infarction disease progression, and is suitable for clinical long-term promotion and application.